Nuvectis Pharma price target raised to $33 from $20 at Roth Capital

Roth Capital raised the firm’s price target on Nuvectis Pharma (NVCT) to $33 from $20 and keeps a Buy rating on the shares. The company “signifi...

Raccontata datipranks.com